Intranasal calcitonin in the treatment of acute charcot neuroosteoarthropathy: A randomized controlled trial

Diabetes Care

Volumn 29, Issue 6, 2006, Pages 1392-1394

  Bem, Robert ^a   Jirkovská, Alexandra ^a   Fejfarová, Vladimíra ^a   Skibová, Jelena ^a   Jude, Edward B ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

ADULT; ARTICLE; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MALE; NEUROPATHIC JOINT DISEASE; RANDOMIZED CONTROLLED TRIAL; SKIN TEMPERATURE; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANIMALS; ARTHROPATHY, NEUROGENIC; CALCITONIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; SALMON;

EID: 33746393741     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0376     Document Type: Article

References (19)

1. Sanders LJ, Frykberg RG: Diabetic neuropathic osteoarthropathy: Charcot foot. In The High Risk Foot in Diabetes Mellitus. Levin ME, O'Neal LW, Bowker JH, Eds. New York, Churchill Livingstone, 1991, p. 297-338
2. Young MJ, Marshall A, Adams JE, Selby PL, Boulton AJM: Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 18:34-38, 1995
3. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, Donohoe M, Foster AVM, Edmonds ME, Boulton AJM: Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032-2037, 2001
4. Gough A, Abraha H, Li F, Purewal TS, Foster AVM, Watkins PJ, Moniz C, Edmonds ME: Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 14:527-531, 1997
5. Jirkovska A, Kasalicky P, Boucek P, Hosova J, Skibova J: Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover. Diabet Med 18:495-500, 2001
6. Jude EB, Boulton AJ: Medical treatment of Charcot's arthropathy. J Am Podiatr Med Assoc 92:381-383, 2002
7. Stepan JJ, Alenfeld F, Boivin G, Feyen HM, Laktos P: Mechanisms of action of antiresortive therapies of postmenopausal osteoporosis. Endocr Regul 37:227-240, 2003
8. Jirkovska A, Hosova J, Kasalicky P, Skibova J: Biochemical markers of bone turnover in patients with Charcot osteoarthropathy before and after treatment. In Poster of the 3rd International Symposium of the Diabetic Foot. Noordwijkerhout, The Netherlands, International Working Group on the Diabetic Foot, 1999, p. 87
9. Cavanagh PR, Young MJ, Adams JE, Vickers KL, Boulton AJM: Radiographic abnormalities in the feet of patients with diabetic neuropathy. Diabetes Care 17:201-209, 1994
10. Young MJ, Breddy JL, Veves A, Boulton AJM: The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study. Diabetes Care 17:557-560, 1994
11. Armstrong DG, Tood WF, Lavery LA, Harkless LB, Bushmann TR: The natural history of acute Charcot's arthropathy in a diabetic foot speciality clinic. Diabet Med 14:357-363, 1997
12. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S: Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085-1096, 2002
13. Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A, Caradonna P, Ghirlanda G: Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial (Brief Report). Diabetes Care 28:1214-1215, 2005
14. Selby PL, Young MJ, Boulton AJ: Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28-31, 1994
15. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531, 2001
16. Jeffcoate W: Vascular calcification and osteolysis in diabetic neuropathy: is RANK-L the missing link? Diabetologia 47:1488-1492, 2004
17. Still K, Phipps RJ, Scutt A: Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int 72:145-150, 2003
18. Zikan V, Stepan J: Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 316:63-69, 2002
19. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G, the Osteoporosis Methodology Group, the Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23:540-551, 2002